New Stock News | It is reported that XCMG Motor is considering listing in Hong Kong as soon as this year, with plans to raise up to 500 million US dollars.
The data shows that the electric, hybrid, and hydrogen fuel cell heavy-duty trucks produced by XCMG Automotive are used in areas such as highway logistics, construction projects, municipal sanitation, and mining.
According to reports, Chinese truck company XCMG Auto is considering listing in Hong Kong as soon as this year. The report cited sources familiar with the matter saying that the company plans to raise up to $500 million through stock issuance, as early as this year. The report cited sources adding that discussions, including on the scale of the transaction and timing, are still ongoing.
Information shows that XCMG Auto produces electric, hybrid, and hydrogen fuel cell powered heavy trucks used in fields such as highway logistics, construction, municipal sanitation, and mining. The company stated last year that it had raised about 6.4 billion yuan from 30 investors. It is known that investors participating in the mixed ownership reform at that time included industrial shareholder such as China Logistics, Baowu, Chinalco, Jiangsu Port, as well as financial investors such as China State-owned Assets Supervision and Administration Commission (SASAC), National Green Development Fund, Advanced Manufacturing Fund, and other state-owned enterprises, state-level large funds, and financial investors.
Related Articles

PETROCHINA (00857) reported a net profit attributable to shareholders of 48.333 billion yuan in the first quarter, representing a year-on-year increase of 1.9%.

Shanghai Pharmaceuticals Holding (02607) reported a first-quarter net profit attributable to the parent company of 1.418 billion yuan, an increase of 6.35% year-on-year.

HAOHAI BIOTEC (06826) spent 2.5194 million Hong Kong dollars on April 29 to repurchase 112,500 shares.
PETROCHINA (00857) reported a net profit attributable to shareholders of 48.333 billion yuan in the first quarter, representing a year-on-year increase of 1.9%.

Shanghai Pharmaceuticals Holding (02607) reported a first-quarter net profit attributable to the parent company of 1.418 billion yuan, an increase of 6.35% year-on-year.

HAOHAI BIOTEC (06826) spent 2.5194 million Hong Kong dollars on April 29 to repurchase 112,500 shares.

RECOMMEND





